Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.

Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.

Item
http://www.wikidata.org/entity/Q33395508
Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern ChinaComparison of thymidine phosphorylase expression and prognostic factors in gallbladder and bile duct cancer.Thymidine phosphorylase expression is associated with time to progression in patients with metastatic colorectal cancer.Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.Thymidine phosphorylase gene variant, platelet counts and survival in gastrointestinal cancer patients treated by fluoropyrimidinesPharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsERCC1 polymorphisms as prognostic markers in T4 breast cancer patients treated with platinum-based chemotherapyThymidylate synthase and thymidine phosphorylase mRNA expression in primary lesions using laser capture microdissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with liver metastasis.Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy.Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy.Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysisCapecitabine in the treatment of esophageal and gastric cancers.Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients.Nucleoside analogs: ready to enter the era of precision medicine?TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials.
P2860

Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.

Item
http://www.wikidata.org/entity/Q33395508
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Thymidylate synthase, dihydrop ...... oxaliplatin and capecitabine.
@ast
Thymidylate synthase, dihydrop ...... oxaliplatin and capecitabine.
@en
type
label
Thymidylate synthase, dihydrop ...... oxaliplatin and capecitabine.
@ast
Thymidylate synthase, dihydrop ...... oxaliplatin and capecitabine.
@en
prefLabel
Thymidylate synthase, dihydrop ...... oxaliplatin and capecitabine.
@ast
Thymidylate synthase, dihydrop ...... oxaliplatin and capecitabine.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P478
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
Thymidylate synthase, dihydrop ...... oxaliplatin and capecitabine.
@en
P2093
P2860
P2888
P304
P31
P356
P407
P478
P577
P5875
P6179
P698
P921
P932